Correction: Real‑world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC‑FFM in ruxolitinib‑refractory acute graft‑versus‑host disease

Ítems similars

• Correction: Real‑world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC‑FFM in ruxolitinib‑refractory acute graft‑versus‑host disease
  per: Halvard Bonig, et al.
  Publicat: (2024-06-01)
• Clinical Development Programme of the Innovative Mesenchymal Stromal Cell Product MSC-FFM/MC0518 for Steroid-Refractory Acute Graft-Versus-Host Disease: Design of 2 Randomised Controlled Trials in Adult and Paediatric Patients
  per: Robert Zeiser, et al.
  Publicat: (2026-01-01)
• Efficacy and safety of human umbilical cord-derived mesenchymal stem cells versus placebo added to second-line therapy in patients with steroid-refractory acute graft-versus-host disease: a multicentre, randomized, double-blind, phase 2 trial
  per: Erlie Jiang, et al.
  Publicat: (2024-11-01)
• REFRACTORY THROMBOCYTOPENIA AND NEUTROPENIA: A DIAGNOSTIC CHALLENGE
  per: Emmanuel Gyan, et al.
  Publicat: (2015-02-01)
• EVOLUTION OF PERFORMANCE OF REFRACTORY LINING FOR THE SLAG LINE OF STEEL LADLES AT USIMINAS IPATINGA
  per: Sávia Cristina Lacerda Poubel Bastos, et al.
  Publicat: (2012-12-01)